LAVAL, Quebec- Altasciences is proud to have supported Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of drugs for obesity and metabolic diseases, in its non-clinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i, an injectable, ultra-long-acting, fully biased GLP-1 receptor agonist.
“Congratulations to Metsera for reaching this important milestone in the development of the MET-097i”
In September, Metsera reported positive preliminary results from the clinical trial conducted at Altasciences’ facilities, in which MET-097i demonstrated a 7.5% reduction in body weight from baseline at day 36 (one week after the last dose) and a half-life of 380 hours. This work has allowed Metsera to recently initiate a 16-week randomized Phase II trial of MET-097i.
In addition to clinical conduct, Altasciences supported Metsera with its Proactive Drug Development solution , including nonclinical, bioanalytical, CRO and program management services for several additional therapeutic candidates. Over the past six months, Altasciences has completed nonclinical work for MET-233i, as well as MET-002, an oral GLP-1 receptor agonist peptide, allowing Metsera to begin clinical trials for both programs this year.
“Congratulations to Metsera on reaching this important milestone in the development of MET-097i,” said Ingrid Holmes, Vice President of Global Clinical Operations at Altasciences. “Metsera is a valued partner of Altasciences and we are proud to have contributed to this program to help people battling obesity-related diseases.”
Obesity affects millions of people worldwide and is a factor in serious health risks, including type 2 diabetes, heart disease and certain cancers. Innovative treatments, such as MET-097i, could provide new treatment options for people affected by this complex disease.
About Altasciences
Altasciences is an integrated drug development solutions company that offers pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies , including formulation, manufacturing and analytical services . For more than 25 years, Altasciences has partnered with sponsors to help them make informed, faster and more comprehensive drug development decisions. Altasciences’ comprehensive, integrated solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring and data management, all customizable to sponsors’ specific requirements. Altasciences helps sponsors get better medicines to the people who need them, faster. To learn more about Altasciences, visit altasciences.com .
The text of the press release resulting from a translation should in no way be considered official. The only version of the press release that is authoritative is that of the press release in its original language. The translation must always be compared with the source text, which will constitute precedent.
Contacts
Julie-Ann Cabana
Altasciences
jcabana@altasciences.com
